The present invention relates to ethynyl derivatives of formula (I) as allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5). The variables in formula (I) are defined in the specification.
[EN] METHOD FOR PRODUCING AN OPTICALLY ACTIVE NITRO COMPOUND<br/>[FR] PROCEDE DE PRODUCTION D'UN COMPOSE NITRO OPTIQUEMENT ACTIF
申请人:CARREIRA ERICK M
公开号:WO2004103951A1
公开(公告)日:2004-12-02
An optically active nitro compound having two hydrogen atoms on its α-cabon atom and having β-asymmetric carbon atom can be produced by making α, β-unsaturated nitroolefin having a hydrogen atom on its α-cabon atom react with at least two organosilicon compounds having at lest one silicon-hydrogen bond in the molecule in the presence of an asymmetric copper complex, or react with an organosilicon compound having at least one silicon-hydrogen bond in the molecule in the presence of an asymmetric copper complex and water.
This invention relates to the compounds represented by a general formula [I]:
1
[in which A
1
and A
2
represent optionally fluorine-substituted methine or the like; B represents halogen, cyano, lower alkyl or the like; D represents optionally substituted heterocyclic group or the like; and G represents C
3
-C
20
aliphatic group such as alicyclic group]. These compounds inhibit nociceptin activities due to their high affinity to nociceptin receptor, and are useful as analgesic, antiobestic, corebral function improver, drugs for treatment of alzheimer's disease and dementia, remedies for schizophrenia and neurodegenerative diseases, antidepressant, remedies for diabetes insipidus, polyuria, hypotension and so on.
Method for producing an optically active nitro compound
申请人:Carreira M. Erick
公开号:US20070037976A1
公开(公告)日:2007-02-15
An optically active nitro compound having two hydrogen atoms on its α-cabon atom and having β-asymmetric carbon atom can be produced by making α, β-unsaturated nitroolefin having a hydrogen atom on its α-cabon atom react with at least two organosilicon compounds having at lest one silicon-hydrogen bond in the molecule in the presence of an asymmetric copper complex, or react with an organosilicon compound having at least one silicon-hydrogen bond in the molecule in the presence of an asymmetric copper complex and water.
This invention relates to the compounds represented by a general formula [I]:
[in which A1 and A2 represent optionally fluorine-substituted methine or the like; B represents halogen, cyano, lower alkyl or the like; D represents optionally substituted heterocyclic group or the like; and G represents C3-C20 aliphatic group such as alicyclic group]. These compounds inhibit nociceptin activities due to their high affinity to nociceptin receptor, and are useful as analgesic, antiobestic, corebral function improver, drugs for treatment of alzheimer's disease and dementia, remedies for schizophrenia and neurodegenerative diseases, antidepressant, remedies for diabetes insipidus, polyuria, hypotension and so on.